Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis

Cancer Letters

Volumn 202, Issue 1, 2003, Pages 11-16

  Wei, Min ^a   Morimura, Keiichirou ^a   Wanibuchi, Hideki ^a   Shen, Jun ^a   Doi, Kenichiro ^a   Mitsuhashi, Makoto ^a   Moku, Masaharu ^a   Salim, Elsayed I ^a   Fukushima, Shoji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoprevention; Colon carcinogenesis; JTE 522; Selective cyclooxygenase 2 inhibitor

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CYCLOOXYGENASE 2 INHIBITOR; SODIUM CHLORIDE; TILMACOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; INTESTINE CRYPT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0344861821     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00477-4     Document Type: Article

References (31)

1. Janne P.A., Mayer R.J. Chemoprevention of colorectal cancer. N. Engl. J. Med. 342:2000;1960-1968.
2. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. N. Biol. 231:1971;232-235.
3. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA. 88:1991;2692-2696.
4. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 340:1999;1888-1899.
5. Needleman P., Isakson P.C. The discovery and function of COX-2. J. Rheumatol. 49:(24 Suppl.):1997;6-8.
6. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
7. Kutchera W., Jones D.A., Matsunami N., Groden J., McIntyre T.M., Zimmerman G.A., White R.L., Prescott S.M. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA. 93:1996;4816-4820.
8. Kawamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
9. Reddy B.S., Hirose Y., Lubet R., Steele V., Kelloff G., Paulson S., Seibert K., Rao C.V. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60:2000;293-297.
10. Rao C.V., Indranie C., Simi B., Manning P.T., Connor J.R., Reddy B.S. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 62:2002;165-170.
11. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:2000;1946-1952.
12. Matsushita M., Masaki M., Yagi Y., Tanaka T., Wakitani K. Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats. Inflamm. Res. 46:1997;461-466.
13. Sasai H., Masaki M., Wakitani K. Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522. Carcinogenesis. 21:2000;953-958.
14. Sunayama K., Konno H., Nakamura T., Kashiwabara H., Shoji T., Tsuneyoshi T., Nakamura S. The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC(Delta474) knockout mice. Carcinogenesis. 23:2002;1351-1359.
15. Nishimura G., Yanoma S., Mizuno H., Kawakami K., Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn. J. Cancer Res. 90:1999;1152-1162.
16. Hida T., Kozaki K., Ito H., Miyaishi O., Tatematsu Y., Suzuki T., Matsuo K., Sugiura T., Ogawa M., Takahashi T. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin. Cancer Res. 8:2002;2443-2447.
17. Tomozawa S., Nagawa H., Tsuno N., Hatano K., Osada T., Kitayama J., Sunami E., Nita M.E., Ishihara S., Yano H., Tsuruo T., Shibata Y., Muto T. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer. 81:1999;1274-1279.
18. Nagatsuka I., Yamada N., Shimizu S., Ohira M., Nishino H., Seki S., Hirakawa K. Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int. J. Cancer. 100:2002;515-519.
19. Li Z., Shimada Y., Kawabe A., Sato F., Maeda M., Komoto I., Hong T., Ding Y., Kaganoi J., Imamura M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis. 22:2001;547-551.
20. Fenoglio-Preiser C.M., Noffsinger A. Aberrant crypt foci: a review. Toxicol. Pathol. 27:1999;632-642.
21. Pretlow T.P., Barrow B.J., Ashton W.S., O'Riordan M.A., Pretlow T.G., Jurcisek J.A., Stellato T.A. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res. 51:1991;1564-1567.
22. Salim E.I., Wanibuchi H., Taniyama T., Yano Y., Morimura K., Yamamoto S., Otani S., Nishizawa Y., Morii H., Fukushima S. Inhibition of development of N, N ′-dimethylhydrazine-induced rat colonic aberrant crypt foci by pre, post and simultaneous treatments with 24R,25-dihydroxyvitamin D3. Jpn. J. Cancer Res. 88:1997;1052-1062.
23. Zhang X.M., Stamp D., Minkin S., Medline A., Corpet D.E., Bruce W.R., Archer M.C. Promotion of aberrant crypt foci and cancer in rat colon by thermolyzed protein. J. Natl. Cancer Inst. 84:1992;1026-1030.
24. Magnuson B.A., Carr I., Bird R.P. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res. 53:1993;4499-4504.
25. Takayama T., Katsuki S., Takahashi Y., Ohi M., Nojiri S., Sakamaki S., Kato J., Kogawa K., Miyake H., Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 339:1998;1277-1284.
26. Bird R.P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett. 93:1995;55-71.
27. Shiff S.J., Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J. Exp. Med. 190:1999;445-450.
28. Howe L.R., Subbaramaiah K., Brown A.M., Dannenberg A.J. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer. 8:2001;97-114.
29. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. 90:1998;1529-1536.
30. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst. 90:1998;1609-1620.
31. Prescott S.M., Fitzpatrick F.A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta. 1470:2000;M69-M78.